• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

打破循环:公私合作应对美国阿片类药物泛滥

Breaking the cycle: A public-private partnership to combat the American opioid epidemic.

机构信息

Harvard Medical School, Boston, MA, USA; Harvard Business School, Boston, MA, USA.

Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA.

出版信息

Healthc (Amst). 2021 Dec;9(4):100592. doi: 10.1016/j.hjdsi.2021.100592. Epub 2021 Nov 2.

DOI:10.1016/j.hjdsi.2021.100592
PMID:34739979
Abstract

There has been an increased focus on the opioid epidemic in the United States, yet policy-based interventions such as prescription limits, restrictions on doctor shopping, and notification programs for high-volume prescribers have had no significant impact. In this paper, the authors explore a novel public health policy: a joint public-private partnership between the federal government and hospitals to establish long-term treatment centers for patients admitted to the emergency department after an overdose. These centers would provide medication for opioid use disorder, give individuals the necessary support for recovery, and reduce healthcare expenditures. Similar longitudinal strategies may be used in other areas of public health.

摘要

美国越来越关注阿片类药物泛滥问题,但基于政策的干预措施,如处方限制、限制医生滥开处方和向大量开药医生发出通知的计划,都没有产生重大影响。在本文中,作者探讨了一项新的公共卫生政策:联邦政府与医院之间建立公私合作伙伴关系,为因过量用药而被送进急诊室的患者设立长期治疗中心。这些中心将提供治疗阿片类药物使用障碍的药物,为个人康复提供必要的支持,并减少医疗保健支出。类似的纵向策略可能在其他公共卫生领域使用。

相似文献

1
Breaking the cycle: A public-private partnership to combat the American opioid epidemic.打破循环:公私合作应对美国阿片类药物泛滥
Healthc (Amst). 2021 Dec;9(4):100592. doi: 10.1016/j.hjdsi.2021.100592. Epub 2021 Nov 2.
2
The Opioid Epidemic: Challenge to Military Medicine and National Security.阿片类药物流行:对军事医学和国家安全的挑战。
Mil Med. 2020 Jun 8;185(5-6):e662-e667. doi: 10.1093/milmed/usz487.
3
The opioid crisis: Origins, trends, policies, and the roles of pharmacists.阿片类药物危机:起源、趋势、政策以及药剂师的作用。
Am J Health Syst Pharm. 2019 Mar 19;76(7):424-435. doi: 10.1093/ajhp/zxy089.
4
Promoting opioid overdose prevention and recovery: An exploratory study of an innovative intervention model to address opioid abuse.促进阿片类药物过量预防和康复:探索性研究一种创新的干预模式,以解决阿片类药物滥用问题。
Int J Drug Policy. 2019 Feb;64:21-29. doi: 10.1016/j.drugpo.2018.12.004. Epub 2018 Dec 12.
5
Opioid Prescribing Behaviors - Prescription Behavior Surveillance System, 11 States, 2010-2016.阿片类药物处方行为-处方行为监测系统,11 个州,2010-2016 年。
MMWR Surveill Summ. 2020 Jan 31;69(1):1-14. doi: 10.15585/mmwr.ss6901a1.
6
Hispanics, Addictions, and the Opioid Epidemic: Brief Report.西班牙裔、成瘾问题与阿片类药物流行:简要报告
Hisp Health Care Int. 2020 Mar;18(1):40-43. doi: 10.1177/1540415319888437. Epub 2019 Nov 20.
7
The US Opioid Crisis: Current Federal and State Legal Issues.美国阿片类药物危机:当前联邦和州的法律问题。
Anesth Analg. 2017 Nov;125(5):1675-1681. doi: 10.1213/ANE.0000000000002403.
8
Government Legislation in Response to the Opioid Epidemic.政府应对阿片类药物泛滥的立法。
Curr Pain Headache Rep. 2019 May 1;23(6):40. doi: 10.1007/s11916-019-0781-1.
9
Lessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic.从应对人类免疫缺陷病毒疫情中吸取的教训,可以为解决阿片类药物流行提供信息。
Infect Dis Clin North Am. 2020 Sep;34(3):637-647. doi: 10.1016/j.idc.2020.06.015.
10
Developing interagency collaboration to address the opioid epidemic: A scoping review of joint criminal justice and healthcare initiatives.开展跨部门合作以应对阿片类药物流行:刑事司法与医疗保健联合举措的范围审查
Int J Drug Policy. 2020 Sep;83:102849. doi: 10.1016/j.drugpo.2020.102849. Epub 2020 Jul 9.

引用本文的文献

1
Analgesic Effect of Sulforaphane: A New Application for Poloxamer-Hyaluronic Acid Hydrogels.萝卜硫素的镇痛作用:泊洛沙姆-透明质酸水凝胶的新应用。
Gels. 2024 Jul 13;10(7):460. doi: 10.3390/gels10070460.